Scholarlink

Background <p>Several maternal vaccines are in clinical development. Maternal respiratory syncytial virus (RSV) vaccine has been introduced in several high and upper middle-income countries. With the recent World Health Organization (WHO) RSV prevention recommendation and Gavi, the Vaccine Alliance’s commitment to open a funding window for RSV maternal vaccine programs, the vaccine will soon be available for low- and middle-income markets. Understanding costs of implementing new maternal vaccines within existing health systems in low-and middle-income countries (LMICs) is critical to inform introduction decisions. This study projects the cost of maternal immunization (MI) introduction and delivery in Bangladesh and Nepal.</p> Methods <p>Using an activity based prospective costing approach, we project MI introduction and delivery costs for a five-year period in each country. In-country stakeholders informed the future MI delivery strategies used for costing. Interviews with immunization and maternal health program representatives informed activities and resource needs. Primary data from a sample of sub-national health administrative units including vaccine stores and health facilities also informed anticipated MI operational costs. Financial and economic costs to the health system are estimated and reported in 2023 US$ units.</p> Results <p>Stakeholders confirmed utilizing existing maternal tetanus vaccine delivery systems as the most feasible strategy for future MI delivery in both countries. The non-vaccine cost of delivering one dose of maternal vaccine was estimated at $0.45 and $1.81 (financial) and $2.01 and $4.49 (economic) in Bangladesh and Nepal, respectively. Excluding commodity cost, health worker training and demand generation activities were among the largest cost drivers in both countries. Relatively lower unit costs in Bangladesh are partly due to larger target population size leading to some efficiency in introduction costs. The anticipated coverage and baseline health system capacity gaps also contribute to the variation in unit costs between countries.</p> Conclusions <p>MI delivery costs in LMICs are little known and this study contributes to filling this gap. These cost projections can equip countries to make informed introduction decisions as they evaluate the affordability and sustainability of MI programs in respective countries.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Maternal vaccine delivery costs in South Asian settings: estimates from Bangladesh and Nepal

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Ranju Baral,
  • Jessica A. Fleming,
  • Abhiyan Gautam,
  • Md. Monjurul Islam,
  • Gauri Shrestha,
  • Sadaf Khan,
  • Mohammed M. Kashem,
  • Sandeep Kumar,
  • Bibek Lal,
  • Kamran Mehedi,
  • Iffat R. Nasir,
  • Lauren Newhouse,
  • Satyabrata Routray,
  • Jayanto K. Saha,
  • Sarah Sultana,
  • Surendra Uranw,
  • Clint Pecenka

摘要

Background

Several maternal vaccines are in clinical development. Maternal respiratory syncytial virus (RSV) vaccine has been introduced in several high and upper middle-income countries. With the recent World Health Organization (WHO) RSV prevention recommendation and Gavi, the Vaccine Alliance’s commitment to open a funding window for RSV maternal vaccine programs, the vaccine will soon be available for low- and middle-income markets. Understanding costs of implementing new maternal vaccines within existing health systems in low-and middle-income countries (LMICs) is critical to inform introduction decisions. This study projects the cost of maternal immunization (MI) introduction and delivery in Bangladesh and Nepal.

Methods

Using an activity based prospective costing approach, we project MI introduction and delivery costs for a five-year period in each country. In-country stakeholders informed the future MI delivery strategies used for costing. Interviews with immunization and maternal health program representatives informed activities and resource needs. Primary data from a sample of sub-national health administrative units including vaccine stores and health facilities also informed anticipated MI operational costs. Financial and economic costs to the health system are estimated and reported in 2023 US$ units.

Results

Stakeholders confirmed utilizing existing maternal tetanus vaccine delivery systems as the most feasible strategy for future MI delivery in both countries. The non-vaccine cost of delivering one dose of maternal vaccine was estimated at $0.45 and $1.81 (financial) and $2.01 and $4.49 (economic) in Bangladesh and Nepal, respectively. Excluding commodity cost, health worker training and demand generation activities were among the largest cost drivers in both countries. Relatively lower unit costs in Bangladesh are partly due to larger target population size leading to some efficiency in introduction costs. The anticipated coverage and baseline health system capacity gaps also contribute to the variation in unit costs between countries.

Conclusions

MI delivery costs in LMICs are little known and this study contributes to filling this gap. These cost projections can equip countries to make informed introduction decisions as they evaluate the affordability and sustainability of MI programs in respective countries.